Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Coupang Inc (CPNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Coupang Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $301.01 (market cap $8.04B), while Coupang Inc trades at $17.82 (market cap $32.17B). The key difference: Coupang Inc is far larger — about 4× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Coupang Inc nearer its low. Which is the better fit depends on your goals.
| BIO | CPNG | |
|---|---|---|
Market Cap | $8.04B | $32.17B |
Sector | Health | Consumer Cyclical |
52-Week High | $339.75 | $33.53 |
52-Week Low | $241.71 | $15.12 |
Enterprise Value | $7.85B | $31.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
CPNG trades at $17.92, down 4.68% today, with a bearish technical signal and mixed earnings. Revenue grew to $34.53B in 2025, but net income margin is negative at -0.47%. Recent news includes a $412M fine for a data breach in South Korea (Reuters, 2026-06-11). The stock faces regulatory headwinds but maintains strong analyst support with an 87.5% buy rating and a $25.80 consensus target.
Outlook: CPNG offers growth potential from e-commerce expansion but carries risks from regulatory fines and profitability challenges. Investors should weigh strong cash flow against recent earnings misses and legal issues. The stock's current price is 30% below the consensus target, presenting upside if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →
